Bio-Bridge Science, Inc. Announces the Appointment of Two New Members to the Board of Directors
April 05 2007 - 10:16AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB: BGES) a developer of vaccines with
broad preventative and therapeutic applications, is pleased to
announce that Mr. Trevor Roy and Mr. Anthony Cheung have been named
to the Company�s board of directors. Both Mr. Roy and Mr. Cheung
bring to Bio-Bridge abundant successful business experience and
numerous international relationships. Their addition to the board
of directors will help Bio-Bridge quickly reach strategic goals in
the pursuit to develop vaccines to treat and improve human health.
"On behalf of Bio-Bridge Science, we welcome Mr. Roy and Mr. Cheung
to the board of directors. I am confident that they will contribute
greatly to our goal to become a leading international vaccine
development and production company," said Dr. Liang Qiao, Chairman
and CEO of Bio-Bridge Science, Inc. Mr. Roy was a graduate of the
University of Sydney. His initial career was in education where he
was a teacher and administrator at both high school and tertiary
levels. Then in a business career spanning 30 years, Mr. Roy, with
his investment and management experience, both in his home country
of Australia and internationally, has been in a wide range of
industries including rural/agricultural, theatrical, marketing and
promotions, food manufacturing and distribution, medical, and
telephony and communications. For the past 18 years, Mr. Roy has
been CEO (now Chairman) of the Creata Group of Companies and has
been instrumental in establishing its business as a global provider
of marketing and promotional programs in 18 offices throughout 12
countries. Mr. Cheung's early career was in finance, accounting and
auditing with John B. P. Byrne & Co., now Grant Thornton in
Hong Kong. This formed the foundation of a successful business
management and investment career over 25 years that now includes:
ownership of manufacturing facilities in Hong Kong and China
(Dongguan) with an excess of 10,000 employees producing over 200
million consumer products annually; ownership of a Class 2 hospital
in China (Fujian); and (commercial) real estate investments and
developments in Hong Kong, China and the United States. Forward
Looking Statements: This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that
are other than statements of historical facts. These statements are
subject to uncertainties and risks including, but not limited to,
product and service demand and acceptance, changes in technology,
economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and
in statements filed from time to time with the Securities and
Exchange Commission. All such forward-looking statements, whether
written or oral, and whether made by or on behalf of the company,
are expressly qualified by these cautionary statements and any
other cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to SEC filings
for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024